Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication
- 5 June 2017
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (25) , 6444-6449
Abstract
The aggregation of the amyloid β peptide (Aβ) into amyloid fibrils is a defining characteristic of Alzheimer’s disease. Because of the complexity of this aggregation process, effective therapeutic inhibitors will need to target the specific microscopic steps that lead to the production of neurotoxic species. We introduce a strategy for generating fibril-specific antibodies that selectively suppress fibril-dependent secondary nucleation of the 42-residue form of Aβ (Aβ42). We target this step because it has been shown to produce the majority of neurotoxic species during aggregation of Aβ42. Starting from large phage display libraries of single-chain antibody fragments (scFvs), the three-stage approach that we describe includes (i) selection of scFvs with high affinity for Aβ42 fibrils after removal of scFvs that bind Aβ42 in its monomeric form; (ii) ranking, by surface plasmon resonance affinity measurements, of the resulting candidate scFvs that bind to the Aβ42 fibrils; and (iii) kinetic screening and analysis to find the scFvs that inhibit selectively the fibril-catalyzed secondary nucleation process in Aβ42 aggregation. By applying this approach, we have identified four scFvs that inhibit specifically the fibril-dependent secondary nucleation process. Our method also makes it possible to discard antibodies that inhibit elongation, an important factor because the suppression of elongation does not target directly the production of toxic oligomers and may even lead to its increase. On the basis of our results, we suggest that the method described here could form the basis for rationally designed immunotherapy strategies to combat Alzheimer’s and related neurodegenerative diseases. Significance The promise of antibody-based strategies to combat Alzheimer’s disease by inhibiting the aggregation of the amyloid β peptide (Aβ) has not yet been realized in clinical trials. In part, this situation has arisen because the antibodies explored so far have been developed without the benefit of the mechanistic information needed to block specific steps in Aβ aggregation. We introduce a strategy to target specifically fibril-dependent secondary nucleation, the microscopic step found to generate most neurotoxic Aβ assemblies. Phage display libraries are screened to find antibodies that bind to Aβ fibrils, followed by affinity ranking and chemical kinetic analysis. Our results suggest that such antibodies may serve as starting points for the development of effective therapeutics for neurodegenerative diseases.Keywords
Funding Information
- EC | European Research Council (340890)
This publication has 37 references indexed in Scilit:
- Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s diseaseProceedings of the National Academy of Sciences, 2016
- Atomic Resolution Structure of Monomorphic Aβ42 Amyloid FibrilsJournal of the American Chemical Society, 2016
- An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer’s diseaseScience Advances, 2016
- Structural Insight into an Alzheimer’s Brain-Derived Spherical Assembly of Amyloid β by Solid-State NMRJournal of the American Chemical Society, 2015
- Preventing peptide and protein misbehaviorProceedings of the National Academy of Sciences, 2015
- Interaction of the Molecular Chaperone DNAJB6 with Growing Amyloid-beta 42 (Aβ42) Aggregates Leads to Sub-stoichiometric Inhibition of Amyloid FormationJournal of Biological Chemistry, 2014
- Quantification of the Concentration of Aβ42 Propagons during the Lag Phase by an Amyloid Chain Reaction AssayJournal of the American Chemical Society, 2013
- Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanismProceedings of the National Academy of Sciences, 2013
- Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid ImmunotherapyPLOS ONE, 2013
- Down syndrome and beta-amyloid depositionCurrent Opinion in Neurology, 2004